<DOC>
	<DOCNO>NCT01288755</DOCNO>
	<brief_summary>The purpose study investigate effect steady-state concentration raltegravir ( administer 400 mg , twice daily ) steady-state pharmacokinetics TMC278 ( 25 mg , daily ) , vice versa . Steady state term mean drug give long enough plasma level remain level subsequent dose . TMC278 investigate treatment human immunodeficiency virus ( HIV ) infection . Raltegravir commercially available antiretroviral drug treatment HIV infection . Pharmacokinetics ( PK ) mean drug absorb bloodstream , distribute body eliminate body .</brief_summary>
	<brief_title>TMC278-TiDP6-C153 - A Study Healthy Volunteers Investigating Pharmacokinetic Interaction Between TMC278 Raltegravir</brief_title>
	<detailed_description>TMC278 investigate treatment HIV infection . Raltegravir commercially available HIV drug . The result study provide dose recommendation coadministration TMC278 raltegravir HIV-infected patient . This Phase I , open-label ( participant investigator know name medication give certain moment ) , randomize ( sequence treatment study medication assign chance ) , crossover trial 24 healthy volunteer investigate pharmacokinetic interaction TMC278 raltegravir , steady state . The study consist 3 phase : screening phase , open-label treatment phase consist 2 treatment period , end-of-study withdrawal assessment . The duration participation study individual participant 3 month ( include screen ) . All participant randomly assign 1 2 possible treatment sequence receive follow 2 treatment ( Trt-s ) : TMC278 25 mg , daily , alone 11 day ( TrtA ) , raltegravir 400 mg , twice daily , alone 4 day immediately follow coadministration raltegravir dose plus TMC278 25 mg , daily , 11 day ( TrtB+C ) . There washout period ( period study drug take view medication eliminate body start new treatment ) least 14 day last intake study medication one session first intake study medication subsequent session . Pharmacokinetic profile compound determine blood sample take regular interval study . Safety tolerability assess study period follow-up . Blood urine sample , electrocardiogram ( ECG ) vital sign ( blood pressure heart rate ) take screening , medication intake TrtA Days 1 , 11 , 12 ( Day 12 without ECG ) , TrtB+C Days 1 , 4 , 5 , 15 , 16 ( Day 16 without ECG ) 2 follow-up visit ( without ECG ) 1 week 4 week last dose study medication last session . A physical examination perform screening , Days 10 12 TrtA , Days 3 , 14 , 16 TrtB+C , follow-up visit . Healthy volunteer stay overnight study center 3 night TrtA 5 night TrtB+C . Each volunteer receive randomize order 2 treatment , minimum 14 day apart . TrtA TMC278 25 mg , daily , 11 day . TrtB+C raltegravir 400 mg , twice daily , alone first 4 day ( TrtB ) follow coadministration 400 mg raltegravir , twice daily , TMC278 25 mg , daily , Days 5 15 ( TrtC ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Healthy , base physical examination , medical history , vital sign , ECG , blood biochemistry , hematology urinalysis Body Mass Index 18 30.0 kg/m2 Nonsmoking least 3 month prior screen Women must postmenopausal least 2 year , surgically sterile . Infected Hepatitis A , B , C Virus Infected human immunodeficiency virus ( HIV ) History clinically relevant hearth rhythm disturbance Having previously participate 1 study raltegravir , TMC125 , TMC120 and/or TMC278 develop rash , erythema urticaria participate trial aforementioned compound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>TMC278-TiDP6-C153</keyword>
	<keyword>TMC278-C153</keyword>
	<keyword>TMC278</keyword>
	<keyword>HIV</keyword>
</DOC>